Bradshaw J Michael, McFarland Jesse M, Paavilainen Ville O, Bisconte Angelina, Tam Danny, Phan Vernon T, Romanov Sergei, Finkle David, Shu Jin, Patel Vaishali, Ton Tony, Li Xiaoyan, Loughhead David G, Nunn Philip A, Karr Dane E, Gerritsen Mary E, Funk Jens Oliver, Owens Timothy D, Verner Erik, Brameld Ken A, Hill Ronald J, Goldstein David M, Taunton Jack
Principia Biopharma, South San Francisco, California, USA.
Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California, USA.
Nat Chem Biol. 2015 Jul;11(7):525-31. doi: 10.1038/nchembio.1817. Epub 2015 May 25.
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here we made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors. Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, we identified potent and selective BTK inhibitors that demonstrated biochemical residence times spanning from minutes to 7 d. An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation. The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach. Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.
具有延长的靶点驻留时间的药物通常显示出卓越的疗效,但目前缺乏优化药物-靶点驻留时间的通用策略。在此,我们通过用可逆共价抑制剂靶向布鲁顿酪氨酸激酶(BTK)中的一个非催化性半胱氨酸,朝着这个难以实现的目标取得了进展。通过使用半胱氨酸反应性氰基丙烯酰胺亲电试剂的反向取向,我们鉴定出了强效且选择性的BTK抑制剂,其生化驻留时间从数分钟到7天不等。一种在体内驻留时间延长的反向氰基丙烯酰胺在从循环中清除后,与BTK的结合仍超过18小时。反向氰基丙烯酰胺策略还被进一步用于发现驻留时间为数天的成纤维细胞生长因子受体(FGFR)激酶抑制剂,证明了该方法的通用性。用反向氰基丙烯酰胺靶向非催化性半胱氨酸可作为一个广泛适用的平台,有助于实现“设计驻留时间”,即能够在体内调节和延长靶点结合的持续时间。